Digital Platform for GxP Compliance in BioPharma

This document is a guide that explains how a digital platform can assist BioPharma laboratories in achieving and maintaining GxP compliance. It outlines the critical importance of data integrity as emphasized by the FDA throughout the lifecycle of regulated products. The document details common issues faced during FDA inspections, particularly concerning data integrity, transparency, and record retention. It identifies challenges such as insufficient data governance and weak access controls that can lead to non-compliance. The guide presents the ALCOA principles, which define the requirements for data integrity and have been updated to include additional attributes. Furthermore, it discusses the necessity of a cloud-based data management platform that ensures compliance with GxP regulations, such as FDA 21 CFR Part 11. The document emphasizes the role of a trusted supplier in configuring software to minimize risk and streamline compliance efforts, ultimately supporting patient safety and regulatory adherence.